Katherine Ann Rubino
Patent Attorney
Caldwell Intellectual Property Law
katie@caldwellip.com
July 8, 2019
Patent Strategies for Small Molecule Drugs Versus Biological Drugs By: Katie Rubino Molecules used as drug products are often categorized into two classes: small […]
June 11, 2019
CAFC Affirms Invalidation of Oxycodone Patent for Lack of Written Description By: Katie Rubino On April 19th, 2019 the Court of Appeals of the Federal […]
May 28, 2019
Supreme Court Denies Certiorari Petition on Tribal Sovereign Immunity in IPR Proceedings By: Katie Rubino Recently at the end of April, the Supreme Court denied […]
May 6, 2019
CAFC Affirms Nonobviousness of Vitamin B12 and Folate Administration Prior to Chemotherapy By: Katie Rubino On April 26, 2019, the Court of Appeals for the […]
April 22, 2019
IPR Incomplete: PTAB Fails to Initiate Indefinite IPR Petition By: Katie Rubino Recently on March 6, 2019 the Patent Trial and Appeal Board (PTAB) issued […]
April 8, 2019
PTAB Enacts New Pilot Program on Motions to Amend During Post Grant Proceedings By: Katie Rubino Recently the Patent Trial and Appeal Board (PTAB) instituted […]
March 24, 2019
Lessons Learned on the Eve of the 10,000th Post Grant Petition Filed at the PTAB By: Katie Rubino Background In 2011, Congress and then President […]
March 17, 2019
CAFC Affirms IPR Dismissal for Lack of Standing and Mootness By: Katie Rubino On February 7th, 2019 the Court of Appeals for the Federal Circuit […]
March 3, 2019
CAFC Upholds Unpatentability of Diagnostic Method Claims By: Katie Rubino On February 6th, 2019 the U.S. Court of Appeals for the Federal Circuit (CAFC) in Athena […]
February 18, 2019
First Cannabis Patent to Survive IPR Challenge In Part By: Katie Rubino On January 3rd, 2019 the Patent Trial and Appeal Board (PTAB) issued a final […]